Last reviewed · How we verify
NCT06860295
"Immunoregulation in Atherosclerosis: A Single-Cell RNA Sequencing Study"
trial testing Single Cell RNA Sequencing in Atherosclerosis of Coronary Artery in 30 participants. Not yet recruiting.
25 October 2026
Quick facts
| Lead sponsor | Hospital Israelita Albert Einstein |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 25 June 2025 |
| Primary completion | 25 October 2026 |
| Estimated completion | 25 April 2027 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Single Cell RNA Sequencing
Conditions studied
- Atherosclerosis of Coronary Artery — all drugs for Atherosclerosis of Coronary Artery →
Sponsor
Hospital Israelita Albert Einstein
Who can join
Adults 45 to 75, any sex, with Atherosclerosis of Coronary Artery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Atherosclerosis is the leading cause of acute cardiovascular events, such as myocardial infarction and stroke, and is a significant risk factor for cardiovascular mortality. The detailed understanding of the immune mechanisms and cellular transformations involved in the pathogenesis of atherosclerosis is still limited, and the use of single-cell RNA sequencing (scRNAseq) has revealed new cellular functions and subpopulations associated with disease progression. This study aims to identify cellular subpopulations, molecular pathways, and changes in gene expression related to the development of atherosclerosis in human coronary arteries. Using scRNAseq, the study seeks to characterize the transcriptomic landscape of cells present in atherosclerotic plaques and identify molecular signatures that reveal individual predispositions to specific phenotypes, such as disease susceptibility and response to therapies. The research will be conducted at the Albert Einstein Israeli Hospital in São Paulo and will involve samples from coronary arteries and atherosclerotic plaques of the explanted hearts of patients who have undergone heart transplants as well as from discarded material of coronary artery bypass graft surgery (CABG). With an estimated sample size of 20-30 plaques, the data obtained will allow for a detailed analysis of the molecular mechanisms involved in atherosclerosis, contributing to the development of specific therapeutic targets.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06860295
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atherosclerosis of Coronary Artery
Currently open trials in the same condition.
- NCT06767345 — Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization · Phase 4 · recruiting
- NCT06855394 — Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events · active not recruiting
Other Hospital Israelita Albert Einstein trials
Trials by the same sponsor.
- NCT07447674 — ED Post-Discharge Digital Follow-Up: A Communication Comparison · NA · not yet recruiting
- NCT07398222 — Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study · recruiting
- NCT07233837 — Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units · NA · recruiting
- NCT06726707 — COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis · Phase 2, PHASE3 · withdrawn
- NCT07112846 — Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06860295 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Israelita Albert Einstein
- Last refreshed: 10 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06860295.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing